FCGR2B Inhibitors
1 drugsAbout FCGR2B
FCGR2B (Fc gamma receptor IIB) is an inhibitory receptor in the FcγR family that modulates immune responses through interaction with IgG antibodies.
FCGR2B is a drug target in oncology, though there is currently no genetic evidence directly linking it to specific diseases.
FCGR2B is targeted by one FDA-approved biologic drug, MARGENZA, developed by MACROGENICS INC for oncology indications.
Top FCGR2B Drugs
MACROGENICS INC is the only company with an approved drug targeting FCGR2B.
The lack of competitors indicates high barriers to entry or an unvalidated market.
FCGR2B Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets FCGR2B, using biologic (other) modality.
Explore small molecule or alternative modalities to differentiate from existing therapies.
FCGR2B Clinical Trials 9 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on FCGR2B. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 4 | 4 | 0 | 0 | 100% |
| Phase 2 | 4 | 2 | 1 | 1 | 67% |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
FCGR2B Drug Approval Timeline (2020 - 2020)
The first and only drug, MARGENZA, was approved in 2020.
Recent approval suggests growing interest, but market saturation is not yet a concern.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 4 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on FCGR2B. A trial counts if an approved drug acting on FCGR2B is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.